Literature DB >> 2702645

Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells.

G Capranico1, P De Isabella, S Penco, S Tinelli, F Zunino.   

Abstract

Formation and persistence of DNA single- and double-strand breaks stimulated by doxorubicin, 9-deoxydoxorubicin, or 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells were compared in relation to drug DNA affinity, cellular pharmacokinetics, and cytotoxicity. Although cellular uptake and retention and DNA affinity of the anthracycline derivatives were similar to those of the parent drug, cytotoxic potency was quite different, 9-deoxydoxorubicin being much less cytotoxic than doxorubicin, and 4-demethyl-6-deoxydoxorubicin the most effective agent. After 1-h exposure of cells to cytotoxic drug levels, the extent of DNA strand breaks produced by 4-demethyl-6-deoxydoxorubicin was greater than that produced by doxorubicin, whereas 9-deoxydoxorubicin induced very few DNA breaks. As for the parent drug, proteolytic treatment of cell lysates on the filter was needed to detect DNA cleavage produced by the analogues. A linear increase of DNA breaks was observed for 2 h following 4-demethyl-6-deoxydoxorubicin or doxorubicin addition; by contrast, DNA break levels reached a plateau after 45 min of exposure to 9-deoxydoxorubicin. DNA lesions produced by the derivatives persisted, and doxorubicin-induced DNA breaks even increased after drug removal, indicating an absence of DNA break resealing under our conditions. These observations indicate that modifications of the chromophore moiety of the anthracycline may enhance both drug cytotoxicity and specificity of drug-target interactions, and thus provide further strong evidence that the anthracycline effect on DNA integrity is a critical aspect of the mechanism of drug action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702645

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.

Authors:  Hideki Asakawa; Hirotaka Koizumi; Ayaka Koike; Makiko Takahashi; Wenwen Wu; Hirotaka Iwase; Mamoru Fukuda; Tomohiko Ohta
Journal:  Breast Cancer Res       Date:  2010-03-05       Impact factor: 6.466

2.  The development of new anticancer drugs.

Authors:  F M Arcamone
Journal:  World J Microbiol Biotechnol       Date:  1992-12       Impact factor: 3.312

3.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Fluorinated anthracyclines: interactions with DNA.

Authors:  K C Tonkin; R C Boston; R T Brownlee; D R Phillips
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

Review 5.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

6.  Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.

Authors:  G R Fisher; L H Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin.

Authors:  S M Cutts; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-07-11       Impact factor: 16.971

Review 8.  Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.

Authors:  Jessica Marinello; Maria Delcuratolo; Giovanni Capranico
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

9.  Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.

Authors:  Caroline D Scatena; Jeffrey L Kumer; Jennifer P Arbitrario; Anthony R Howlett; Rachael E Hawtin; Judith A Fox; Jeffrey A Silverman
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-08       Impact factor: 3.333

10.  Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.

Authors:  Alba Dalmases; Irene González; Silvia Menendez; Oriol Arpí; Josep Maria Corominas; Sonia Servitja; Ignasi Tusquets; Cristina Chamizo; Raúl Rincón; Lluis Espinosa; Anna Bigas; Pilar Eroles; Jessica Furriol; Anna Lluch; Ana Rovira; Joan Albanell; Federico Rojo
Journal:  Oncotarget       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.